1759 related articles for article (PubMed ID: 22460902)
1. Systematic identification of genomic markers of drug sensitivity in cancer cells.
Garnett MJ; Edelman EJ; Heidorn SJ; Greenman CD; Dastur A; Lau KW; Greninger P; Thompson IR; Luo X; Soares J; Liu Q; Iorio F; Surdez D; Chen L; Milano RJ; Bignell GR; Tam AT; Davies H; Stevenson JA; Barthorpe S; Lutz SR; Kogera F; Lawrence K; McLaren-Douglas A; Mitropoulos X; Mironenko T; Thi H; Richardson L; Zhou W; Jewitt F; Zhang T; O'Brien P; Boisvert JL; Price S; Hur W; Yang W; Deng X; Butler A; Choi HG; Chang JW; Baselga J; Stamenkovic I; Engelman JA; Sharma SV; Delattre O; Saez-Rodriguez J; Gray NS; Settleman J; Futreal PA; Haber DA; Stratton MR; Ramaswamy S; McDermott U; Benes CH
Nature; 2012 Mar; 483(7391):570-5. PubMed ID: 22460902
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the oncogenic fusion protein EWS-FLI1 causes G
Zöllner SK; Selvanathan SP; Graham GT; Commins RMT; Hong SH; Moseley E; Parks S; Haladyna JN; Erkizan HV; Dirksen U; Hogarty MD; Üren A; Toretsky JA
Sci Signal; 2017 Oct; 10(499):. PubMed ID: 28974650
[TBL] [Abstract][Full Text] [Related]
3. PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma.
Brenner JC; Feng FY; Han S; Patel S; Goyal SV; Bou-Maroun LM; Liu M; Lonigro R; Prensner JR; Tomlins SA; Chinnaiyan AM
Cancer Res; 2012 Apr; 72(7):1608-13. PubMed ID: 22287547
[TBL] [Abstract][Full Text] [Related]
4. Combining PARP-1 inhibition and radiation in Ewing sarcoma results in lethal DNA damage.
Lee HJ; Yoon C; Schmidt B; Park DJ; Zhang AY; Erkizan HV; Toretsky JA; Kirsch DG; Yoon SS
Mol Cancer Ther; 2013 Nov; 12(11):2591-600. PubMed ID: 23966622
[TBL] [Abstract][Full Text] [Related]
5. High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition.
Awad O; Yustein JT; Shah P; Gul N; Katuri V; O'Neill A; Kong Y; Brown ML; Toretsky JA; Loeb DM
PLoS One; 2010 Nov; 5(11):e13943. PubMed ID: 21085683
[TBL] [Abstract][Full Text] [Related]
6. Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma.
Boro A; Prêtre K; Rechfeld F; Thalhammer V; Oesch S; Wachtel M; Schäfer BW; Niggli FK
Int J Cancer; 2012 Nov; 131(9):2153-64. PubMed ID: 22323082
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma.
Rao DD; Jay C; Wang Z; Luo X; Kumar P; Eysenbach H; Ghisoli M; Senzer N; Nemunaitis J
Mol Ther; 2016 Aug; 24(8):1412-22. PubMed ID: 27166877
[TBL] [Abstract][Full Text] [Related]
8. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
9. Junction region of EWS-FLI1 fusion protein has a dominant negative effect in Ewing's sarcoma in vitro.
Jully B; Vijayalakshmi R; Gopal G; Sabitha K; Rajkumar T
BMC Cancer; 2012 Nov; 12():513. PubMed ID: 23145994
[TBL] [Abstract][Full Text] [Related]
10. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.
Grohar PJ; Segars LE; Yeung C; Pommier Y; D'Incalci M; Mendoza A; Helman LJ
Clin Cancer Res; 2014 Mar; 20(5):1190-203. PubMed ID: 24277455
[TBL] [Abstract][Full Text] [Related]
11. An integrated chemical biology approach identifies specific vulnerability of Ewing's sarcoma to combined inhibition of Aurora kinases A and B.
Winter GE; Rix U; Lissat A; Stukalov A; Müllner MK; Bennett KL; Colinge J; Nijman SM; Kubicek S; Kovar H; Kontny U; Superti-Furga G
Mol Cancer Ther; 2011 Oct; 10(10):1846-56. PubMed ID: 21768330
[TBL] [Abstract][Full Text] [Related]
12. The Ewing Family of Tumors Relies on BCL-2 and BCL-X
Heisey DAR; Lochmann TL; Floros KV; Coon CM; Powell KM; Jacob S; Calbert ML; Ghotra MS; Stein GT; Maves YK; Smith SC; Benes CH; Leverson JD; Souers AJ; Boikos SA; Faber AC
Clin Cancer Res; 2019 Mar; 25(5):1664-1675. PubMed ID: 30348635
[TBL] [Abstract][Full Text] [Related]
13. Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma.
Goss KL; Gordon DJ
Oncotarget; 2016 Sep; 7(39):63003-63019. PubMed ID: 27557498
[TBL] [Abstract][Full Text] [Related]
14. A zebrafish transgenic model of Ewing's sarcoma reveals conserved mediators of EWS-FLI1 tumorigenesis.
Leacock SW; Basse AN; Chandler GL; Kirk AM; Rakheja D; Amatruda JF
Dis Model Mech; 2012 Jan; 5(1):95-106. PubMed ID: 21979944
[TBL] [Abstract][Full Text] [Related]
15. The dual inhibitory effect of thiostrepton on FoxM1 and EWS/FLI1 provides a novel therapeutic option for Ewing's sarcoma.
Sengupta A; Rahman M; Mateo-Lozano S; Tirado OM; Notario V
Int J Oncol; 2013 Sep; 43(3):803-12. PubMed ID: 23857410
[TBL] [Abstract][Full Text] [Related]
16. Development of an Ewing sarcoma cell line with resistance to EWS‑FLI1 inhibitor YK‑4‑279.
Conn E; Hour S; Allegakoen D; Graham G; Petro J; Kouassi-Brou M; Hong SH; Selvanathan S; Çelik H; Toretsky J; Üren A
Mol Med Rep; 2020 Mar; 21(3):1667-1675. PubMed ID: 32016454
[TBL] [Abstract][Full Text] [Related]
17. High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability.
He T; Surdez D; Rantala JK; Haapa-Paananen S; Ban J; Kauer M; Tomazou E; Fey V; Alonso J; Kovar H; Delattre O; Iljin K
Gene; 2017 Jan; 596():137-146. PubMed ID: 27760381
[TBL] [Abstract][Full Text] [Related]
18. A molecular function map of Ewing's sarcoma.
Kauer M; Ban J; Kofler R; Walker B; Davis S; Meltzer P; Kovar H
PLoS One; 2009; 4(4):e5415. PubMed ID: 19404404
[TBL] [Abstract][Full Text] [Related]
19. Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma.
Smith R; Owen LA; Trem DJ; Wong JS; Whangbo JS; Golub TR; Lessnick SL
Cancer Cell; 2006 May; 9(5):405-16. PubMed ID: 16697960
[TBL] [Abstract][Full Text] [Related]
20. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening.
Grohar PJ; Woldemichael GM; Griffin LB; Mendoza A; Chen QR; Yeung C; Currier DG; Davis S; Khanna C; Khan J; McMahon JB; Helman LJ
J Natl Cancer Inst; 2011 Jun; 103(12):962-78. PubMed ID: 21653923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
